The trademark application LEQLAZA was filed by Johnson & Johnson, a U.S. corporation (the "Applicant"). The application was published for oppositions on May 12, 2021, and it was registered by office on August 19, 2021 without any oppositions.
The application was filed in Dutch (English was selected as the second language).